Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome.

Ann Intern Med. 1985 Sep;103(3):335-8. Unique Identifier : AIDSLINE MED/85277657
Volberding PA; Abrams DI; Conant M; Kaslow K; Vranizan K; Ziegler J

Abstract: Single-agent intravenous vinblastine, 4 to 8 mg/week, was used to treat 38 patients with Kaposi's sarcoma related to the acquired immunodeficiency syndrome. The dose was titrated in relation to the total leukocyte count. Ten patients had an objective response, and 19 had stable disease during therapy. Apart from expected modest neutropenia, toxicity was minimal. A lower response rate was seen in patients with anemia, an elevated erythrocyte sedimentation rate, or any lymphoma-like B symptom. Opportunistic infections were common regardless of type of response but were commoner in patients who did not respond. Vinblastine used in low doses weekly is effective in treating Kaposi's sarcoma related to the acquired immunodeficiency syndrome and has minimal associated toxicities.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Adult Blood Sedimentation Drug Administration Schedule Hematocrit Human Infection/ETIOLOGY Injections, Intravenous Middle Age Sarcoma, Kaposi's/BLOOD/*DRUG THERAPY/ETIOLOGY Support, U.S. Gov't, P.H.S. Vinblastine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC USE JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/KWDcomplicationsadultbloodsedimentationdrugadministrationschedulehematocrithumaninfection/etiologyinjections,intravenousmiddleagesarcoma,kaposi's/blood/KWDdrugtherapy/etiologysupport,uKWDsKWDgov't,pKWDhKWDsKWDvinblastine/administration&dosage/adverseeffects/KWDtherapeuticusejournalarticle
851130
M85B0169

Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .